Your browser doesn't support javascript.
loading
GNE myopathy in Roma patients homozygous for the p.I618T founder mutation.
Chamova, Teodora; Guergueltcheva, Velina; Gospodinova, Mariana; Krause, Sabine; Cirak, Sebahattin; Kaprelyan, Ara; Angelova, Lyudmila; Mihaylova, Violeta; Bichev, Stoyan; Chandler, David; Naydenov, Emanuil; Grudkova, Margarita; Djukmedzhiev, Presian; Voit, Thomas; Pogoryelova, Oksana; Lochmüller, Hanns; Goebel, Hans H; Bahlo, Melanie; Kalaydjieva, Luba; Tournev, Ivailo.
Affiliation
  • Chamova T; Department of Neurology, University Hospital Alexandrovska, Sofia Medical University, Sofia, Bulgaria. Electronic address: teodoratch@abv.bg.
  • Guergueltcheva V; Department of Neurology, University Hospital Alexandrovska, Sofia Medical University, Sofia, Bulgaria.
  • Gospodinova M; Department of Cardiology, Medical Institute of Ministry of Interior Affairs, Sofia, Bulgaria.
  • Krause S; Laboratory of Molecular Myology, Friedrich-Baur-Institute, Department of Neurology, Ludwig Maximilians University, Munich, Germany.
  • Cirak S; Uniklinik Köln Institut für Humangenetik, Cologne, Germany.
  • Kaprelyan A; Department of Neurology, Medical University, Varna, Bulgaria.
  • Angelova L; Department of Pediatrics and Medical Genetics, Medical University, Varna, Bulgaria.
  • Mihaylova V; Department of Neurology, University Hospital Alexandrovska, Sofia Medical University, Sofia, Bulgaria.
  • Bichev S; National Genetics Laboratory, Molecular Medicine Center, Medical University, Sofia, Bulgaria.
  • Chandler D; Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Australia; Australian Genome Research Facility, Perth, Australia.
  • Naydenov E; Department of Neurosurgery, Ivan Rilski Hospital, Sofia, Bulgaria.
  • Grudkova M; Department of Neurology, Medical University, Varna, Bulgaria.
  • Djukmedzhiev P; Medical Centre Plus, Varna, Bulgaria.
  • Voit T; Institute of Myology and Myology Research Centre, University Pierre et Marie Curie, UPMC-INSERM UMR 974, CNRS FRE 3617, GH Pitié-Salpêtrière, Paris, France.
  • Pogoryelova O; John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Lochmüller H; John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Goebel HH; Department of Neuropathology, Charité - Universitätsmedizin Berlin, Germany.
  • Bahlo M; Population Health and Immunity Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Department of Mathematics and Statistics, The University of Melbourne, Parkville, Victoria, Austra
  • Kalaydjieva L; Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Australia.
  • Tournev I; Department of Neurology, University Hospital Alexandrovska, Sofia Medical University, Sofia, Bulgaria; Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, Bulgaria.
Neuromuscul Disord ; 25(9): 713-8, 2015 Sep.
Article in En | MEDLINE | ID: mdl-26231298
GNE myopathy is an autosomal-recessive disorder caused by mutations in the GNE gene, encoding the key enzyme in the sialic acid biosynthetic pathway, UDP-N-acetylglucosamine 2-epimerase/N-acetyl mannosamine kinase. We studied 50 Bulgarian Roma patients homozygous for p.I618T, an ancient founder mutation in the kinase domain of the GNE gene, dating before the Gypsy exodus from North West India. The clinical features in the Bulgarian GNE group can be described with disease onset mostly in the third decade, but in individual cases, onset was as early as 10 years of age. The majority of patients had foot drop as the first symptom, but three patients developed hand weakness first. Muscle weakness was early and severe for the tibialis anterior, and minimal or late for quadriceps femoris, and respiratory muscles were only subclinically affected even in the advanced stages of the disease. During a 15-year follow-up period, 32 patients became non-ambulant. The average period between disease onset and loss of ambulation was 10.34 ± 4.31 years, ranging from 3 to 20 years. Our analysis of affected sib pairs suggested a possible role of genetic modifying factors, accounting for significant variation in disease severity.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Distal Myopathies / Multienzyme Complexes Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Female / Humans / Male Language: En Year: 2015 Type: Article

Full text: 1 Database: MEDLINE Main subject: Distal Myopathies / Multienzyme Complexes Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Female / Humans / Male Language: En Year: 2015 Type: Article